Resverlogix Announces Filing of Quarterly Financial Statements and Management’s Discussion & Analysis
December 14 2017 - 7:27PM
Resverlogix Corp. (“Resverlogix” or the "Company") (TSX:RVX)
announced today that it has filed its unaudited interim
Consolidated Financial Statements and Management’s Discussion &
Analysis for the quarter ended October 31, 2017 with Canadian
securities regulatory authorities.
Copies of these documents may be obtained online
at www.sedar.com, or the Company's website, www.resverlogix.com, or
by emailing ir@resverlogix.com
About Resverlogix
Resverlogix is developing apabetalone (RVX-208),
a first-in-class, small molecule that is a selective BET
(bromodomain and extra-terminal) inhibitor. BET bromodomain
inhibition is an epigenetic mechanism that can regulate
disease-causing genes. Apabetalone is the first and only BET
inhibitor selective for the second bromodomain (BD2) within the BET
protein called BRD4. This selective inhibition of apabetalone on
BD2 produces a specific set of biological effects with potentially
important benefits for patients with high-risk cardiovascular
disease (CVD), diabetes mellitus (DM), chronic kidney disease,
end-stage renal disease treated with hemodialysis,
neurodegenerative disease, Fabry disease, peripheral artery disease
and other orphan diseases, while maintaining a well described
safety profile. Apabetalone is the only selective BET bromodomain
inhibitor in human clinical trials. Apabetalone is currently being
studied in a Phase 3 trial, BETonMACE, in high-risk CVD patients
with type 2 DM and low high-density lipoprotein (HDL), and is
expected to be initiated in a Phase 2a kidney dialysis trial
designed to evaluate biomarker changes and safety parameters in up
to 30 patients with end-stage renal disease treated with
hemodialysis.
Resverlogix common shares trade on the Toronto Stock Exchange
(TSX:RVX).
Follow us on
Twitter: https://twitter.com/resverlogix_rvx
For further information please contact:
Investor Relations Email: ir@resverlogix.com Phone: 403-254-9252
Or visit our website: www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Sep 2023 to Sep 2024